The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase Ib study of gemcitabine and oxaliplatin with erlotinib in patients with advanced biliary tract cancer.
Kristen Keon Ciombor
No relevant relationships to disclose
Dana Backlund Cardin
Research Funding - OSI Pharmaceuticals
Emily Chan
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Genentech; ImClone Systems; Pfizer; Sanofi
Research Funding - Amgen; Astellas Pharma; Bristol-Myers Squibb; Genentech; Idera; ImClone Systems; Lilly; Merck; MethylGene; Pfizer
Pamela McClanahan
No relevant relationships to disclose
Kang-Hsien Fan
No relevant relationships to disclose
Jayme Flynn
No relevant relationships to disclose
Ruth T. Young
No relevant relationships to disclose
April DeMers
No relevant relationships to disclose
Stephen James Smith
No relevant relationships to disclose
Jordan Berlin
Consultant or Advisory Role - Sanofi ; Sanofi
Research Funding - ImClone Systems; ImClone Systems; OSI/Astellas; OSI/Astellas
Other Remuneration - ImClone Systems; Lilly
Laura Williams Goff
Research Funding - OSI/Astellas; Sanofi